Home  >  News
Msc_Apr23 .
you can get e-magazine links on WhatsApp. Click here
Biotechnology + Font Resize -

Mongolia Health Ministry grants EUA to Jiangsu Recbio’s two-component recombinant Covid-19 vaccine, ReCOV

Wednesday, March 22, 2023, 11:00 Hrs  [IST]

Jiangsu Recbio Technology Co., Ltd., an innovative vaccine company, announced that in accordance with the Mongolian law on the prevention of novel coronavirus (SARS-CoV-2) outbreak, the company was granted an Emergency Use Authorization (EUA) for its two-component recombinant Covid-19 vaccine ReCOV by Order No. A106 of the Minister of Public Health of Mongolia and a resolution of the Mongolian Committee for Medicinal Products for Human Use.

This product is designed and developed by the Group jointly with Professor Wang Xiangxi’ s group at the Institute of Biophysics, Chinese Academy of Science, and is the first novel adjuvant recombinant subunit Covid-19 vaccine developed in China and approved overseas.

Novel adjuvant have become a key factor in the successful research and development of innovative vaccines in China, and have become one of the key research projects in the development plan of China’s pharmaceutical industry during the 14th Five-Year Plan.

ReCOV is a recombinant Covid-19 vaccine being developed by the company with its technology platforms, including its novel adjuvant, protein engineering and immunological evaluation platforms, and the adjuvant used therein is its self-developed novel adjuvant BFA03. The company has successively conducted multiple late-stage clinical studies for ReCOV in China, the Philippines, the United Arab Emirates, Nepal and Russia.

Studies have shown that ReCOV has demonstrated favourable safety profile, with mild adverse reactions and no vaccine-related serious adverse events. In particular, in a comparative clinical study with a positive control of the Pfizer’s mRNA vaccine, a sequential booster of ReCOV among subjects who have completed vaccination of inactivated vaccines induced durable and widespread cross-neutralizing antibodies against various Omicron variants, including BF.7, BA.5, BA.2.75, and BA.2, with all subgroups achieving superior levels of neutralizing antibodies as compared to the Pfizer’s mRNA vaccine (with statistically significant differences).

The granting of the EUA to ReCOV in Mongolia will benefit the Group’s expansion into overseas market, enhancement of the Group’s overseas brand awareness and promotion of the Group’s internationalization strategy, and will play a positive role in promoting the registration in other countries and regions.

Founded in 2012, Jiangsu Recbio Technology Co., Ltd. is an innovative vaccine company driven by self-developed technologies.


* Name :     
* Email :    
  Website :  
Copyright © 2016 Saffron Media Pvt. Ltd |